Sanofi (SNY) Stock

Healthcare · Drug Manufacturers - General · Member of Other US Stocks

Sanofi (SNY) closed at USD 39.77 on 2026-10-14, a change of -17.8 % over the past year, with a market capitalization of USD 96.54B.

Sanofi recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sanofi key figures

Previous close

USD 39.77 (2026-10-14)

1-year change

-17.8 %

Market cap

USD 96.54B

Enterprise value

USD 114.13B

P/E ratio (trailing)

20.66

P/E ratio (forward)

7.63

EPS (trailing)

1.95

EPS (forward)

5.28

PEG ratio

27.54

Price to book

1.25

Revenue growth

14.6 %

Earnings growth

-91.2 %

Dividend per share (trailing)

4.12

Short ratio

4.14

Employees

74,846

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sanofi and compare it with other stocks.